AP512A - Derivatives of 1-aminocarbonylmethyl-3-amino-2,4-dioxo-1-5 benzodiazepines having CCKA agonist activity. - Google Patents

Derivatives of 1-aminocarbonylmethyl-3-amino-2,4-dioxo-1-5 benzodiazepines having CCKA agonist activity. Download PDF

Info

Publication number
AP512A
AP512A APAP/P/1994/000635A AP9400635A AP512A AP 512 A AP512 A AP 512A AP 9400635 A AP9400635 A AP 9400635A AP 512 A AP512 A AP 512A
Authority
AP
ARIPO
Prior art keywords
formula
phenyl
group
compound
4alkyl
Prior art date
Application number
APAP/P/1994/000635A
Other languages
English (en)
Other versions
AP9400635A0 (en
Inventor
Elizabeth Ellen Sugg
Christopher Joseph Aquino
Jerzy Rysard Szewczyk
Harry Finch
Original Assignee
Glaxo Wellcome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Inc filed Critical Glaxo Wellcome Inc
Publication of AP9400635A0 publication Critical patent/AP9400635A0/xx
Application granted granted Critical
Publication of AP512A publication Critical patent/AP512A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
APAP/P/1994/000635A 1993-04-15 1994-04-13 Derivatives of 1-aminocarbonylmethyl-3-amino-2,4-dioxo-1-5 benzodiazepines having CCKA agonist activity. AP512A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939307833A GB9307833D0 (en) 1993-04-15 1993-04-15 Modulators of cholecystokinin and gastrin

Publications (2)

Publication Number Publication Date
AP9400635A0 AP9400635A0 (en) 1994-04-30
AP512A true AP512A (en) 1996-07-29

Family

ID=10733915

Family Applications (2)

Application Number Title Priority Date Filing Date
APAP/P/1994/000635A AP512A (en) 1993-04-15 1994-04-13 Derivatives of 1-aminocarbonylmethyl-3-amino-2,4-dioxo-1-5 benzodiazepines having CCKA agonist activity.
APAP/P/1994/000634A AP462A (en) 1993-04-15 1994-04-13 1,5 Benzodiazepine derivatives.

Family Applications After (1)

Application Number Title Priority Date Filing Date
APAP/P/1994/000634A AP462A (en) 1993-04-15 1994-04-13 1,5 Benzodiazepine derivatives.

Country Status (33)

Country Link
US (2) US5646140A (is)
EP (1) EP0694039B1 (is)
JP (1) JP3406317B2 (is)
KR (1) KR100364948B1 (is)
CN (1) CN1058487C (is)
AP (2) AP512A (is)
AT (1) ATE198894T1 (is)
AU (1) AU681139B2 (is)
CA (1) CA2158973C (is)
CZ (1) CZ286695B6 (is)
DE (1) DE69426624T2 (is)
DK (1) DK0694039T3 (is)
EC (1) ECSP941066A (is)
ES (1) ES2154674T3 (is)
FI (1) FI954853L (is)
GB (1) GB9307833D0 (is)
GR (1) GR3035641T3 (is)
HU (1) HU223467B1 (is)
IL (2) IL109316A (is)
IS (2) IS4148A (is)
MY (2) MY131569A (is)
NO (1) NO311133B1 (is)
NZ (1) NZ265272A (is)
OA (1) OA10355A (is)
PE (2) PE50994A1 (is)
PH (1) PH30897A (is)
PL (1) PL178790B1 (is)
PT (1) PT694039E (is)
RU (1) RU2135486C1 (is)
SK (1) SK281211B6 (is)
TW (1) TW487703B (is)
WO (1) WO1994024149A1 (is)
ZA (2) ZA942570B (is)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69430068T2 (de) * 1993-12-28 2002-08-14 SHIONOGI & CO., LTD. Benzodiazepinderivate
SK281433B6 (sk) * 1994-04-14 2001-03-12 Glaxo Wellcome Inc. 5-heterocyklo-1,5-benzodiazepínové deriváty, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie
US5739129A (en) * 1994-04-14 1998-04-14 Glaxo Wellcome Inc. CCK or gastrin modulating 5-heterocyclic-1, 5 benzodiazepines
WO1995028399A1 (en) * 1994-04-15 1995-10-26 Glaxo Wellcome Inc. A method of inducing cholecystokinin agonist activity using 1,4-benzodiazepine compounds
PE27497A1 (es) * 1994-04-15 1997-08-07 Glaxo Inc Derivados de 1,5 benzodiazepina
GB9420763D0 (en) * 1994-10-14 1994-11-30 Glaxo Inc Acetamide derivatives
GB9420747D0 (en) * 1994-10-14 1994-11-30 Glaxo Inc 1,5 benzodiazepine derivatives
GB9420748D0 (en) * 1994-10-14 1994-11-30 Glaxo Inc 1,5 benzodiazepine derivatives
US5910495A (en) * 1994-10-14 1999-06-08 Glaxo Wellcome Inc. Use of 1,5-benzo b!1,4-diazepines to control gastric emptying
US5780464A (en) * 1994-10-14 1998-07-14 Glaxo Wellcome Inc. Enteric coated compositions of 1,5-benzodiazepine derivatives having CCK antagonistic or agonistic activity
US5750353A (en) * 1995-12-11 1998-05-12 New England Medical Center Hospitals, Inc. Assay for non-peptide agonists to peptide hormone receptors
AU715611B2 (en) 1995-12-11 2000-02-03 New England Medical Center Hospitals, Inc., The Assay for and uses of peptide hormone receptor ligands
JP3999819B2 (ja) * 1996-12-10 2007-10-31 ゼリア新薬工業株式会社 １，５―ベンゾジアセピン誘導体
SK141899A3 (en) 1997-04-15 2000-09-12 Csir Corporate Building Pharmaceutical compositions having appetite suppressant activity
AR022044A1 (es) * 1999-05-06 2002-09-04 Glaxo Group Ltd Derivados de 1,5-benzodiazepina
GB2396815B (en) 1999-10-27 2004-09-08 Phytopharm Plc A composition comprising a pregnenone derivative and an NSAID
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
US6768024B1 (en) 2000-08-04 2004-07-27 Lion Bioscience Ag Triamine derivative melanocortin receptor ligands and methods of using same
US20020180095A1 (en) * 2001-05-29 2002-12-05 Berard Steven O. Thermally conductive carbon fiber extrusion compounder and method of using same
DE60325834D1 (de) * 2002-02-20 2009-03-05 Abbott Lab Kondensierte azabicyclischeverbindungen als inhibitoren des vanilloid-rezeptors 1 (vr1)
US7074805B2 (en) * 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US6933311B2 (en) * 2003-02-11 2005-08-23 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US7015233B2 (en) * 2003-06-12 2006-03-21 Abbott Laboratories Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
RU2261246C1 (ru) * 2004-04-15 2005-09-27 Общество с ограниченной ответственностью "Исследовательский Институт Химического Разнообразия" (ООО "Исследовательский Институт Химического Разнообразия") Замещенные 7-сульфонил бензо[b][1,4]диазепины (варианты), способы их получения (варианты), фокусированная библиотека и фармацевтическая композиция
GEP20094723B (en) * 2004-05-25 2009-07-10 Pfizer Prod Inc Tetraazabenzo [e] azulene derivatives and analogs thereof
CN1333077C (zh) * 2005-04-15 2007-08-22 华南农业大学 缩胆囊素活性片段的串联表达及其应用
RU2303597C1 (ru) * 2006-05-12 2007-07-27 Иващенко Андрей Александрович Фармацевтическая композиция, способы ее получения и применения
CA2661898A1 (en) * 2006-08-25 2008-02-28 Abbott Laboratories Indazole derivatives that inhibit trpv1 and uses thereof
JP2010513557A (ja) 2006-12-20 2010-04-30 アボット・ラボラトリーズ 疼痛治療のためのｔｒｐｖ１バニロイド受容体アンタゴニストとしてのｎ−（５，６，７，８−テトラヒドロナフタレン−１−イル）尿素誘導体および関連化合物
US8232411B2 (en) * 2008-03-20 2012-07-31 Abbott Laboratories Methods for making central nervous system agents that are TRPV1 antagonists
CN103102285B (zh) * 2013-01-30 2015-07-29 淮阴师范学院 对氨基苯乙腈的制备方法
RU2720237C2 (ru) 2013-11-18 2020-04-28 Форма Терапеутикс, Инк. Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет
BR122019007990B1 (pt) 2013-11-18 2021-05-04 Forma Therapeutics, Inc Composto, e, composição farmacêutica
MY197231A (en) 2015-07-22 2023-06-06 Enanta Pharm Inc Benzodiazepine derivatives as rsv inhibitors
US9815850B2 (en) 2016-02-05 2017-11-14 Denali Therapeutics Inc. Compounds, compositions and methods
LT3552017T (lt) 2016-12-09 2022-05-10 Denali Therapeutics Inc. Junginiai, naudotini kaip ripk1 inhibitoriai
WO2018152413A1 (en) 2017-02-16 2018-08-23 Enanta Pharmaceuticals, Inc. Processes for the preparation of benzodiazepine derivatives
WO2018226801A1 (en) * 2017-06-07 2018-12-13 Enanta Pharmaceuticals, Inc. Aryldiazepine derivatives as rsv inhibitors
US10851115B2 (en) 2017-06-30 2020-12-01 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
WO2019006295A1 (en) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
CN111386118B (zh) 2017-09-29 2023-05-09 英安塔制药有限公司 作为rsv抑制剂的组合药物剂
WO2019094920A1 (en) 2017-11-13 2019-05-16 Enanta Pharmaceuticals, Inc. Azepin-2-one derivatives as rsv inhibitors
WO2019199908A1 (en) 2018-04-11 2019-10-17 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
WO2020190935A1 (en) 2019-03-18 2020-09-24 Enanta Pharmaceuticals, Inc. Benzodiazepine derivatives as rsv inhibitors
US11179400B2 (en) 2019-04-09 2021-11-23 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
UY39032A (es) 2020-01-24 2021-07-30 Enanta Pharm Inc Compuestos heterocíclicos como agentes antivirales
WO2022010882A1 (en) 2020-07-07 2022-01-13 Enanta Pharmaceuticals, Inc, Dihydroquinoxaline and dihydropyridopyrazine derivatives as rsv inhibitors
WO2022086840A1 (en) 2020-10-19 2022-04-28 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
US12612412B2 (en) 2021-02-26 2026-04-28 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
EP4463229A1 (en) 2022-01-12 2024-11-20 Denali Therapeutics Inc. Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide
AR129003A1 (es) 2022-04-07 2024-07-03 Enanta Pharm Inc Compuestos heterocíclicos antivirales
WO2023211997A1 (en) 2022-04-27 2023-11-02 Enanta Pharmaceuticals, Inc. Antiviral compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0376849A1 (fr) * 1988-12-29 1990-07-04 Roussel-Uclaf Nouveaux dérivés de la 2,4-dioxo 2,3,4,5-tétrahydro 1H-1,5-benzodiazépine, leur procédé et les intermédiaires de préparation, leur application comme médicaments et les compositions les renfermant
WO1993014074A1 (en) * 1992-01-21 1993-07-22 Glaxo Spa 1,5-benzodiazepine derivatives and their use in medicine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4517195A (en) * 1984-07-02 1985-05-14 Hoechst-Roussel Pharmaceuticals Inc. Pyrrolo[1,2-b][1,2,5]triazepines and pharmaceutical compositions thereof
SU1362732A1 (ru) * 1986-04-16 1987-12-30 Ленинградский Технологический Институт Им.Ленсовета Способ получени 2-диалкиламино-4-метил-3н-1,5-бензодиазепинов
CH673947A5 (is) * 1986-09-23 1990-04-30 Sandoz Ag
FR2659653B1 (fr) * 1990-03-13 1992-05-22 Rhone Poulenc Sante Derives de l'uree, leur preparation et les medicaments les contenant.
US5206234A (en) * 1990-10-22 1993-04-27 Merck & Co., Inc. Benzolactam analogs as antagonists of cck
JP2904941B2 (ja) * 1991-01-28 1999-06-14 出光興産株式会社 スチレン系重合体の精製方法
SK281433B6 (sk) * 1994-04-14 2001-03-12 Glaxo Wellcome Inc. 5-heterocyklo-1,5-benzodiazepínové deriváty, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0376849A1 (fr) * 1988-12-29 1990-07-04 Roussel-Uclaf Nouveaux dérivés de la 2,4-dioxo 2,3,4,5-tétrahydro 1H-1,5-benzodiazépine, leur procédé et les intermédiaires de préparation, leur application comme médicaments et les compositions les renfermant
WO1993014074A1 (en) * 1992-01-21 1993-07-22 Glaxo Spa 1,5-benzodiazepine derivatives and their use in medicine

Also Published As

Publication number Publication date
PE50994A1 (es) 1995-01-06
ECSP941066A (es) 1994-11-16
AU681139B2 (en) 1997-08-21
MY131569A (en) 2007-08-30
NO954090L (no) 1995-12-13
WO1994024149A1 (en) 1994-10-27
SK125395A3 (en) 1996-06-05
CN1058487C (zh) 2000-11-15
SK281211B6 (sk) 2001-01-18
IS4148A (is) 1994-10-16
HK1003943A1 (en) 1998-11-13
IS4147A (is) 1994-10-16
NZ265272A (en) 1997-07-27
AU6567694A (en) 1994-11-08
CN1120843A (zh) 1996-04-17
GB9307833D0 (en) 1993-06-02
OA10355A (en) 2001-10-19
DK0694039T3 (da) 2001-05-21
ZA942571B (en) 1994-11-11
PH30897A (en) 1997-12-23
IL109316A0 (en) 1994-07-31
JP3406317B2 (ja) 2003-05-12
PE50594A1 (es) 1995-01-06
FI954853A7 (fi) 1995-10-12
CA2158973C (en) 2006-06-06
US5585376A (en) 1996-12-17
EP0694039A1 (en) 1996-01-31
DE69426624T2 (de) 2001-06-21
GR3035641T3 (en) 2001-06-29
AP9400634A0 (en) 1994-04-30
IL109316A (en) 1999-03-12
FI954853A0 (fi) 1995-10-12
CA2158973A1 (en) 1994-10-27
RU2135486C1 (ru) 1999-08-27
PL311084A1 (en) 1996-02-05
CZ286695B6 (en) 2000-06-14
ATE198894T1 (de) 2001-02-15
MY112237A (en) 2001-05-31
AP462A (en) 1996-02-19
PT694039E (pt) 2001-06-29
NO311133B1 (no) 2001-10-15
KR100364948B1 (ko) 2003-03-29
NO954090D0 (no) 1995-10-13
HU223467B1 (hu) 2004-07-28
AP9400635A0 (en) 1994-04-30
FI954853L (fi) 1995-10-12
PL178790B1 (pl) 2000-06-30
JPH08508744A (ja) 1996-09-17
DE69426624D1 (de) 2001-03-01
IL109315A0 (en) 1994-07-31
ES2154674T3 (es) 2001-04-16
CZ267595A3 (en) 1996-04-17
TW487703B (en) 2002-05-21
ZA942570B (en) 1994-11-11
EP0694039B1 (en) 2001-01-24
US5646140A (en) 1997-07-08
HU9502978D0 (en) 1995-12-28
HUT74102A (en) 1996-11-28

Similar Documents

Publication Publication Date Title
EP0694039B1 (en) 1,5-benzodiazepine derivatives having cck antagonistic and or agonistic activity
US5795887A (en) Method of inducing cholecystokinin agonist activity using 1,4- Benzodiazepine compounds
AU679085B2 (en) Benzodiazepine analogs
EP0756602B1 (en) Cck or gastrin modulating 5-heterocyclic-1,5-benzodiazepines
US5739129A (en) CCK or gastrin modulating 5-heterocyclic-1, 5 benzodiazepines
CA2158972A1 (en) 1,5-benzodiazepine derivatives having cck and/or gastrin antogonistic activity
US5910495A (en) Use of 1,5-benzo b!1,4-diazepines to control gastric emptying
HK1003943B (en) 1,5-benzodiazepine derivatives having cck antagonistic and or agonistic activity